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Abstract
During the Ebola outbreak in 2014-2015 in Sierra Leone, residual clinical
specimens and accompanying data were collected from routine diagnostic
testing in Public Health England (PHE) led laboratories. Most of the
samples with all the accompanying data were transferred to PHE
laboratories in the UK for curation by PHE.  The remainder have been kept
securely in Sierra Leone. The biobank holds approximately 9955 samples
of which 1108 tested positive for Ebola virus. Researchers from the UK and
overseas, from academia, government other research organisations and
commercial companies can submit proposals to the biobank to access and
use the samples.
 
The Ministry of Health and Sanitation in Sierra Leone (MOHS) retains
ownership of the data and materials and is working with PHE and other
researchers to develop and conduct a series of research projects that will
inform future healthcare and public health strategies relating to Ebola.  The
Ebola Biobank Governance Group (EBGG) was established to guarantee
equality of access to the biobank for the most scientifically valuable
research including by researchers from low and middle-income countries.
Ensuring benefit to the people of Sierra Leone is an over-arching principle
for decisions of the EBGG.  Four ongoing research collaborations are
based on the first wave of biobank proposals approved by EBGG.  Whilst
the biobank is a valuable resource its completeness and sample quality are
consistent with the outbreak conditions under which they were collected.
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Disclaimer
The views expressed in this article are those of the author(s). 
Publication in Wellcome Open Research does not imply 
endorsement by Wellcome.
Introduction
During the Ebola virus disease outbreak in 2013–2015 in 
Sierra Leone (https://www.who.int/features/ebola/storymap/en/), 
Public Health England (PHE) operated three diagnostic labo-
ratories: in Freetown (Kerrytown), North West Sierra Leone 
(Port Loko Laboratory) and Central Sierra Leone (Makeni 
laboratory). These laboratories processed up to 300 clinical 
samples each day during the outbreak. In 2015 approximately 
9955 residual samples and associated data were collected from 
these laboratories and transferred to PHE in the UK leading to the 
establishment of the MOHS-PHE Ebola Biobank with the 
approval of the Sierra Leone Government. The biobank has 
been funded by a Wellcome Trust Bioresource (grant reference: 
208376).
PHE acts as the curator of the samples on behalf of the Sierra 
Leone government. The MOHS retains ownership of the data 
and samples and is working with PHE and other researchers to 
enable research to inform future healthcare and public health 
strategies relating to Ebola.
To our knowledge, this was the first biobank to be established to 
enable the sharing of samples from this outbreak with the global 
research community however a 2016 review by the WHO indicates 
significant other holdings.’ See https://www.who.int/blueprint/pri-
ority-diseases/key-action/biobanking_ebola_samples/en/ 
The MOHS-PHE Ebola Biobank Governance and 
Access Processes
This biobank is a secure but accessible resource of biologi-
cal samples that are essential for understanding human disease 
and the development of vaccines, diagnostics and treat-
ments. The biobank samples are an especially valuable and 
finite resource, a legacy of the world’s largest ever outbreak 
of Ebola virus disease https://www.who.int/features/ebola/ 
storymap/en/. Outbreaks of this disease continue in Africa, 
so it is evident that further biomedical research is required to 
more readily bring outbreaks under control. https://www.who.int/
emergencies/diseases/ebola/drc-2019 
The existing materials are also a record of other diseases 
that were incident in the population concurrently with Ebola. 
The MOHS-PHE Ebola Biobank Governance Group (EBGG) 
was established to address ethics and governance associated 
with the establishment and running of the biobank, focussing on 
realising the clinical and scientific value of the materials. The 
Group includes three members from Sierra Leone nominated 
by the Chief Medical Officer. Other members of the group rep-
resent the World Health Organisation, the Wellcome Trust, 
the UK Department for International Development and PHE 
with the Chair from the London School of Hygiene and 
Tropical Medicine. 
The EBGG guarantees equality of access to the materials 
and data for researchers from developed as well as low- and 
middle-income countries. It ensures that the resource is used 
for the global public good in accordance with the undertaking 
given by PHE to the MOHS, and that the research will have 
relevance to the people of Sierra Leone. 
The biobank is accessible to all researchers globally from 
academia, government other research organisations and commer-
cial companies. Because the samples were collected during an 
outbreak—where the primary objectives were to deliver care and 
limit the outbreak—ethical approval for research was not col-
lected from patients. So, in addition to EBGG approval, research-
ers wishing to use its samples need to obtain ethical approval 
from the Sierra Leone national ethics committee and from a local 
institutional ethics committee prior to receiving their samples. 
Researchers can only access fully anonymised samples which 
are released with a material transfer agreement that guarantees 
the rights of the Sierra Leone government to any intellectual 
property developed during the research study and ensures the 
publication of all research results. 
Samples and associated data
The 9955 samples comprise whole blood, blood plasma and 
swabs; 1108 of these tested positive for Ebola virus. Laboratory 
results are available for malaria testing, but not for other 
diseases that may have afflicted Ebola virus disease patients. 
All biobank samples are  stored in freezers at −80°C.
A database was established at PHE to store the associated data. 
Not all the samples have a full dataset, but the information in 
Box 1 is available for some samples in the biobank
Currently there are no patient outcome details, but it is expected 
that this information will be available for inclusion in the database 
in the future. 
      Amendments from Version 1
Following peer review, the following changes were made.  
The title was changed from ‘The Ministry of Health and 
Sanitation-Public Health England (MOHS-PHE) Ebola Biobank’ 
to ‘Establishment of Ebola Biobank based on the West African 
Outbreak’.
Links to WHO internet sites were added to the document to 
provide references, and a note was added to say that this 
biobank is one of many significant other holdings.
The section that was headed ‘Establishment of the MOHS-PHE 
Ebola Biobank’ was misleading as this section did not deal with 
the establishment of the biobank, but rather with the governance 
and access processes, so the heading was changed to reflect 
this.
A line stating that ‘it is possible to infer patient outcome by looking 
at sequential diagnosis’ was removed as it may be erroneous. 
Applicants wishing to access the biobank are now advised to 
‘contact the Ebola Biobank Governance Group secretariat’ to 
confirm sample availability. 
Any further responses from the reviewers can be found at the 
end of the article
REVISED
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Usually most samples are collected for inclusion in biobanks in 
accordance with protocols designed to guarantee consistency 
and high quality. They are also handled, processed and stored 
in ideal conditions. As the MOHS-PHE biobank comprises 
residual materials that were used for diagnosis there is varia-
tion in sample quality. Prior to their movement to PHE facilities, 
the samples may have been subjected to different storage 
conditions depending upon available facilities. Some had to be 
transported long distances to centres for testing and may have 
been subjected to cycles of freezing and thawing. The conditions 
the samples have been held in since their arrival in the UK in 
2015 are fully documented. Samples are provided to researchers 
with the caveat that their quality cannot be guaranteed.
Variability in the quality of the diagnostic assays used during 
the outbreak has led to some samples being incorrectly classi-
fied and many of the samples may contain other undiagnosed 
pathogens. All samples are assumed to be highly infectious and 
will only be released, without further treatment, to researchers 
with documented access to Biosafety Level 4 facilities when all 
the appropriate permits are in place. Samples may be released 
when the risk of them containing live virus has been elimi-
nated using a validated inactivation procedure. The method of 
virus inactivation is discussed with the receiving researcher 
and currently has involved the use of a commercial RNA/DNA 
extraction kit. We plan to use X-ray radiation for inactivation at 
some point in the future.
Applying to the MOHS-PHE Ebola Biobank
The EBGG seeks to collaborate with bona fide research-
ers wishing to undertake research that is in the public good 
and that will inform future healthcare and public health strat-
egies in Sierra Leone. Application to the biobank is a one stage 
process made to the MOHS-PHE EBGG.
The biobank is a limited resource so research projects for which 
the scientific value has been scrutinized through peer review 
organised by a known organisation are prioritised. The amount 
and nature of depletable sample required is considered care-
fully and must be justified within the application in relation to 
the intended use. The EBGG secretariat maintains contact with 
the recipient research groups to ensure the materials are used 
for the intended health-related purposes and the Group will 
assess if the research use meets the required criteria for access 
(including legal and ethics standards). Researchers will also need to 
show that they have sufficient funding to cover the cost of prepar-
ing and delivering samples as well as research costs. For applica-
tions involving researchers from low and middle-income countries, 
this criterion may be waived. Applicants wishing to access mate-
rials are advised to contact the MOHS-PHE EBGG secretariat’ 
to confirm sample availability before their project plans are 
finalised.
Current research
The following research collaborations are ongoing:
Colonel Professor F. Sahr, Military Hospital, Freetown, Sierra 
Leone & Dr Felicity Fitzgerald UCL 
The identification of the pathogens underlying febrile 
illnesses in children attending Ebola Holding Units 
testing negative for Ebola to identify opportunities for 
improving clinical outcomes
Stored plasma from children who tested negative for Ebola 
will be tested to identify pathogens in children with febrile ill-
nesses. Understanding of the epidemiology of the common-
est pathogens will allow the ruling out of Ebola infection and 
the delivery of targeted therapy. It will also inform future public 
health planning.
Professor Michael Levin & Dr Nathalie MacDermott, Imperial 
College London
Exploring the genetic factors that play an important 
role in susceptibility, severity and outcome from 
infectious disease
There is growing evidence that exposure to Ebola results in dif-
ferent outcomes, from contacts remaining uninfected to severe, 
fatal infection. Among survivors some recover fully, others 
have virus persistence and others develop long term complica-
tions such as arthritis and uveitis. Identification of the genetic 
basis for susceptibility severity and outcome of Ebola will 
Box 1. Details of information available for samples
•   Laboratory of origin •   Date of hospitalisation
•   Laboratory ID number •   Symptom onset
•   Facility from where the patient was referred •   Date tested
•   Patient age •   Clinical chemistry results
•   Gender •   Ebola viral load
•   Original or follow up sample •   Malaria test result1
•   Ebola test result2
 
1 Diagnosis of Malaria was by rapid diagnostic test kits.
2 Diagnosis of Ebola was by real-time PCR.
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provide further information on its pathogenesis and new targets 
for therapy.
Dr Christopher H. Logue & Ms Emma Wise, PHE
Comparison of the viromes (collection of viruses) of 
Ebola negative and Ebola positive patients to establish 
the role that non-VHF pathogen co-infection may play 
in affecting clinical outcome and survival.
Significant developments have been made in the under-
standing the biology of Ebola but there remain gaps in our 
knowledge of the effects of co-infection with pathogens that 
co-circulate during an Ebola outbreak, and the role that pathogen 
co-infection may play in affecting clinical outcome and survival 
remains largely unknown. We hypothesize that the clinical out-
come of patients infected with Ebola was detrimentally affected 
by co-infection with other circulating pathogens. 
Dr Robert Watson, PHE
Ebola MoDRAD
The development and delivery of a rapid and bedside 
diagnostic tool to significantly increase the capacity to 
handle future Ebola outbreaks
The overall aim of Ebola MoDRAD is to develop and deliver 
rapid and bedside diagnostic tool(s), by way of a multidisciplinary 
research consortium drawn from key European and African 
research organisations.
The requested samples will be used to improve and validate the 
following rapid point-of-care diagnostics for use in the field:
•    Validation of an Ebola blood inactivation tube for serology.
•    IgM (IgG) antigen microarray epitope mapping of patient 
sera
•    Validation of an Ebola antigen / IgM antibody lateral flow 
device
•    Validation of rapid point-of-care isothermal assay
The future of the MOHS-PHE Ebola Biobank
PHE’s work includes a commitment to support research into the 
effective management of future disease outbreaks. The MOHS-
PHE Ebola Biobank is unique in the UK in being housed in 
facilities suitable for the storage and processing of high-risk 
biological samples that require specialist handling by highly 
trained competent staff in appropriate Advisory Committee on 
Dangerous Pathogens hazard group 4 laboratories. Within these 
facilities, protocols are used for the inactivation of Ebola virus 
and other high-risk pathogens potentially contained in the sam-
ples, so they may be shared with researchers globally who lack 
access to such facilities. Therefore, the governance, management, 
laboratory processing and sharing of biobank resources have 
been detailed and documented. They can be re-employed by PHE 
or any other relevant organisation dealing with specimens that 
might be collected during any future infectious disease outbreak.
So, while the current biobank holdings are intended to 
be depleted by sharing with researchers, its laboratory 
and contextual legacy will be sustained. PHE is continuing 
to explore additional innovative and efficient ways to ensure 
researcher safety when dealing with highly dangerous viral path-
ogens so that high quality research may proceed. Additionally, 
planning is underway to include biobank operation and 
management as an element of laboratory training for Sierra Leone 
staff who may then more effectively undertake investigations 
on residual diagnostic samples. 
Data availability
No data are associated with this article.
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General comments
The manuscript by Hannigan  . describes the creation and use of an Ebola biobank based on sampleset al
collected in Sierra Leone during the 2013-2015 West African Ebola virus disease outbreak. The
manuscript describes a very important bio-resource with potential for significantly advancing viral
haemorrhagic fever research and improving public health. The manuscript is generally well written, but
there are some areas that can be improved. Specific comments that may require the attention of authors
are given below:
 
Specific comments
 
Title
I am of the view that the title should be modified to read something like “Establishment of Ebola Biobank
based on the West African Outbreak”.
Abstract
It is better for the abstract to have a single paragraph.
 
To avoid repetitions, in the sentence “Most of the samples with all the accompanying data were
transferred to PHE…” should be modified to read “Most of the samples with all the accompanying data
were transferred to PHE laboratories in the UK for curation”.
 
I suggest the sentence “Researchers from the UK and overseas,…” be rephrased to read “Researchers
globally…”.
 
The sentence “Four ongoing research collaborations are based on the wave of biobank proposals
approved by EBGG” appears to occur without some background. It is better to indicate to the readership
something like “So far, the EBGG has approved four research proposals…”.
 
It would be better to place a comma after the word “resource” in the sentence “Whilst the biobank is a
valuable resource its completeness…”.
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 valuable resource its completeness…”.
 
Introduction 
The Introduction should have some reference(s) relating to the 2013-2015 Ebola outbreak to allow some
readers who may be interested or lack the background information about this outbreak to gain deeper
insight of this epidemic.
 
It would also be better to mention (along with an appropriate reference) of the availability of other Ebola
biobanks, which are publicly accessible. If such a biobank is not available, an indication that this is the first
of its kind would strengthen this section.
 
It is better to have a comma after the year 2015 in this sentence “In 2015 approximately…”.
 
Establishment of the MOHS-PHE Ebola Biobank
In this section, the above title is a bit misleading in that what is described is some background on the
West African Ebola outbreak and the establishment of the Ebola Biobank Governance Group (EBGG).
Furthermore, the governance and modalities of accessing the samples are described. Meanwhile,
information regarding the actual establishment of the biobank has not been described. I would suggest
that this section be divided into two sections: one that describes how the biobank was established and the
other which describes the governance and modalities of accessing and utilization of the biobank.
 
It is better to place a comma after the word “secure” in the sentence “This biobank is a secure but
accessible…”
 
An appropriate reference is needed for this sentence “a legacy of the world’s largest ever outbreak of
Ebola virus disease”. Some readers would be interested in the scale of other Ebola virus outbreaks.
 
It would be better to support the following sentence with a reference: “Outbreaks of this disease continue
in Africa,…”. An article describing the current ongoing Ebola outbreak in the Democratic Republic of
Congo could be used.
 
Samples and associated data
The following sentence can be revised to improve clarity “Results are available for malaria testing but
there are no results available for testing for other diseases that may have been carried by patients”.
Authors can consider something like “Laboratory results are available for malaria testing, but not for other
diseases that may have afflicted Ebola virus disease patients”.
 
In the sentence “All biobank samples are held in freezers at −80°C,” the word “held” can be replaced with
the word “stored.”
 
I suggest that the whole of the sentence “Until then it is possible for researchers to infer patient outcome
by looking at sequential diagnostic tests” be deleted. Such inferences may be erroneous.
 
Applying to the MOHS-PHE Ebola Biobank
Being a co-owned biobank, it would be better that applicants contact an overarching body rather than just
PHE as suggested by this sentence “Applicants wishing to access materials are advised to contact PHE
to confirm sample availability before their project plans are finalised”.
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Does the article adequately reference differing views and opinions?
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Are all factual statements correct, and are statements and arguments made adequately
supported by citations?
No
Is the Open Letter written in accessible language?
Yes
Where applicable, are recommendations and next steps explained clearly for others to follow?
Yes
 No competing interests were disclosed.Competing Interests:
Reviewer Expertise: Molecular epidemiology; emerging and reemerging infectious diseases; Zoonoses.
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expertise to confirm that it is of an acceptable scientific standard.
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© 2019 Lever M. This is an open access peer review report distributed under the terms of the Creative Commons
, which permits unrestricted use, distribution, and reproduction in any medium, provided the originalAttribution License
work is properly cited.
 Mark Stephen Lever
CBR Division, Defence Science and Technology Laboratory (Dstl), Salisbury, UK
This letter describes the establishment of the MOHS-PHE Ebola Biobank, the potential benefits, current
studies and proposed future for the samples.
The rationale and benefits of such a facility are made clear, particularly in the current climate where
additional scrutiny and accountability are important factors to be considered. This letter clearly sets out
the establishment of the Ebola Biobank Governance Group to oversee the equality of access to the
samples for all researchers. This letter achieves the aim of advertising such access, for the scientific
community, and citing the ongoing research which is benefitting from the samples.
For additional completeness, it might be useful to add to this letter any previous research collaborations
and their objectives that have now finished.
Is the rationale for the Open Letter provided in sufficient detail?
Yes
Does the article adequately reference differing views and opinions?
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 Does the article adequately reference differing views and opinions?
Yes
Are all factual statements correct, and are statements and arguments made adequately
supported by citations?
Yes
Is the Open Letter written in accessible language?
Yes
Where applicable, are recommendations and next steps explained clearly for others to follow?
Yes
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